Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585938 | 0.88 | KDM4D (0.53) | TSHRTP53POLBMITFFNTA | |
| SCHEMBL11748691 | 0.85 | PRSS1 (0.57) | TSHRTP53POLBMITFFNTA | |
| SCHEMBL14830544 | 0.85 | MAPK13 (0.45) | POLBSRD5A2ALDH1A1MEN1KMT2A | |
| SCHEMBL11174529 | 0.85 | PRSS1 (0.51) | ALDH1A1 | |
| SCHEMBL11175449 | 0.85 | PRSS1 (0.51) | ALDH1A1 | |
| SCHEMBL11184370 | 0.83 | PRSS1 (0.50) | ALDH1A1 | |
| SCHEMBL11183424 | 0.83 | PRSS1 (0.50) | ALDH1A1 | |
| SCHEMBL25719356 | 0.83 | TSHR (0.55) | TSHRTP53MITFFNTAFNTB | |
| SCHEMBL1663752 | 0.82 | GAA (0.47) | POLBCYP1A2 | |
| SCHEMBL6152657 | 0.82 | MAPT (0.50) | POLBMITFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085689-A1 | EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | claimed |
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20250241908-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES | NINGBO MEISHAN BONDED PORT AREA ZHEJIANG UNITED INVESTMENT MANAGEMENT CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| CN-119997953-A | Alpha protein kinase 1 inhibitors for the treatment of kidney diseases and kidney related diseases | 上海药苑生物科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4543443-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | Shanghai Yao Yuan Biotechnology Co., Ltd. (CN) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025082485-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085689-A1 | EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| EP-2642994-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | Ligand Pharmaceuticals Incorporated (US) | 2013-10-02 | — | — | EP | disclosed |
| CN-103282034-A | Use of hematopoietic growth factor mimetics | LIGAND PHARM INC | 2013-09-04 | — | — | CN | disclosed |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110003851-A1 | SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20030219467-A1 | Method for the inhibition of methanogensis | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2003-11-27 | — | — | US | disclosed |
| WO-2003038109-A2 | METHOD FOR THE INHIBITION OF METHANOGENESIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2003-05-08 | — | — | WO | disclosed |
| US-5091033-A | ADHESIVE FOR CERAMICS AND PROCESSES FOR THE BONDING OF CERAMICS USING SAME | MITSUI SEKIYU KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | PHKA1, PHKA2, PHKG1 | TSHR 4848/4885TP53 4040/4885POLB 2604/4885 |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | TSHR 1185/4885TP53 309/4885POLB 3224/4885 |
| US-20250241908-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES | PHKA1, PHKA2, PHKG1 | TSHR 4648/4885TP53 2260/4885POLB 1287/4885 |
| US-20110003851-A1 | SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS | MPL, CSF3R, CSF1R | TSHR 870/4885TP53 430/4885POLB 3040/4885 |
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | PHKA1, PHKA2, PHKG1 | TSHR 4509/4885TP53 1682/4885POLB 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.